<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02814916</url>
  </required_header>
  <id_info>
    <org_study_id>DUR001-306</org_study_id>
    <secondary_id>2014-005281-30</secondary_id>
    <nct_id>NCT02814916</nct_id>
  </id_info>
  <brief_title>Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections in Children, Known or Suspected to be Caused by Susceptible Gram-positive Organisms, Including MRSA</brief_title>
  <official_title>A Phase 3, Multicenter, Open-Label, Randomized, Comparator Controlled Trial of the Safety and Efficacy of Dalbavancin Versus Active Comparator in Pediatric Subjects With Acute Bacterial Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Durata Therapeutics Inc., an affiliate of Allergan plc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Durata Therapeutics Inc., an affiliate of Allergan plc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the safety and descriptive efficacy of dalbavancin for the treatment of acute
      bacterial skin and skin structure infections in children, aged 3 months to 17 years, known or
      suspected to be caused by susceptible Gram-positive organisms, including
      methicillin-resistant strains of Staphylococcus aureus.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2017</start_date>
  <completion_date type="Anticipated">January 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">January 25, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with abnormal audiologic assessment</measure>
    <time_frame>Baseline to Visit 5 (Day 26 to Day 30)</time_frame>
    <description>Audiologic testing will be conducted in at least 30 children less than 12 years old and will include evoked otoacoustic emissions testing, acoustic immittance measures (tympanometry and contra and ipsilateral acoustic reflex thresholds) and (optional) threshold auditory brainstem responses. Patients with an abnormal audiologic assessment at Day 28 (plus or minus 2 days) that exceeds, by a clinically significant margin, any abnormality observed in the Baseline assessment, will be considered to have an abnormal audiologic assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in number of patients with the presence of either Clostridium difficile (CD), vancomycin-resistant enterococci (VRE), or both CD and VRE in bowel flora</measure>
    <time_frame>Baseline to Visit 5 (Day 26 to Day 30)</time_frame>
    <description>Evaluated in patients 3 months of age to &lt; 2 years of age, by performing polymerase chain reaction (PCR) for Clostridium difficile (C diff) and culture for vancomycin-resistant enterococci (VRE) on a stool specimen or rectal swab.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical response</measure>
    <time_frame>Baseline to Visit 2 (48 to 72 hours)</time_frame>
    <description>Defined as greater than 20% reduction in lesion size compared to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Cure</measure>
    <time_frame>Baseline and Visit 4 (Day 12 to Day 16).</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Improvement</measure>
    <time_frame>Baseline and Visit 4 (Day 12 to Day 16).</time_frame>
    <description>Clinical response of Improvement will be defined as a reduction in severity of two or more, but not all, clinical signs and symptoms of infection, when compared with baseline. No additional antibacterial treatment is required for disease under study. This outcome category will only be used at the EOT evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Failure</measure>
    <time_frame>Baseline and Visit 4 (Day 12 to Day 16).</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the end of treatment (EOT) visit: Unknown</measure>
    <time_frame>Baseline and Visit 4 (Day 12 to Day 16).</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure, Improvement or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Cure</measure>
    <time_frame>Baseline and Visit 5 (Day 26 to Day 30).</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Failure</measure>
    <time_frame>Baseline and Visit 5 (Day 26 to Day 30).</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at the test of cure visit: Unknown</measure>
    <time_frame>Baseline and Visit 5 (Day 26 to Day 30).</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Cure</measure>
    <time_frame>Baseline and Visit 6 (Day 47 to Day 61)</time_frame>
    <description>Clinical response of Cure will be defined as resolution of the clinical signs and symptoms of infection, when compared to baseline. No additional antibacterial treatment is required for disease under study.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Failure</measure>
    <time_frame>Baseline and Visit 6 (Day 47 to Day 61)</time_frame>
    <description>Clinical response of Failure will be defined as persistence or progression of baseline clinical signs and symptoms of infection after at least 2 days (48 hours) of treatment OR development of new clinical findings consistent with active infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical response evaluated at follow-up visit: Unknown</measure>
    <time_frame>Baseline and Visit 6 (Day 47 to Day 61)</time_frame>
    <description>Clinical response of Unknown will be defined as extenuating circumstances precluding classification to Cure or Failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of baseline pathogen after treatment</measure>
    <time_frame>Baseline to Visit 6 (up to Day 61)</time_frame>
    <description>Direct demonstration of eradication or persistence of the causative organism</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Methicillin-Resistant Staphylococcus Aureus</condition>
  <condition>Bacterial Infections</condition>
  <condition>Staphylococcal Skin Infections</condition>
  <arm_group>
    <arm_group_label>dalbavancin, single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>dalbavancin, two dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin single dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.</description>
    <arm_group_label>dalbavancin, single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dalbavancin two dose</intervention_name>
    <description>Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.</description>
    <arm_group_label>dalbavancin, two dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Comparator</intervention_name>
    <description>Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA).
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.
Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns.</description>
    <arm_group_label>Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  A clinical picture compatible with Acute Bacterial Skin and Skin Structure Infections
             (ABSSSI) suspected or confirmed to be caused by Gram-positive bacteria, including
             Methicillin-resistant Staphylococcus aureus (MRSA).

          -  In addition to local signs of ABSSSI, the patient has at least one of the following:

               1. Fever, defined as body temperature ≥ 38.4°C (101.2°F) taken orally, ≥ 38.7°C
                  (101.6°F) tympanically, or ≥ 39°C (102.2°F) rectally (core temperature) OR

               2. Leukocytosis (WBC &gt; 10,000 mm3) or leukopenia (WBC &lt; 2,000 mm3) or left shift of
                  &gt;10% band neutrophils

          -  Infection either involving deeper soft tissue or requiring significant surgical
             intervention:

               1. Major cutaneous abscess characterized as a collection of pus within the dermis or
                  deeper that is accompanied by erythema, edema and/or induration which:

                    1. requires surgical incision and drainage, and

                    2. is associated with cellulitis such that the total affected area involves at
                       least 35 cm2 of erythema, or total affected area of erythema is at least BSA
                       (m2) x 43.0 (cm2/m2), OR

                    3. alternatively, involves the central face and is associated with an area of
                       erythema of at least 15 cm2

               2. Surgical site or traumatic wound infection characterized by purulent drainage
                  with surrounding erythema, edema and/or induration which occurred within 30 days
                  after the trauma or surgery and is associated with cellulitis such that i. the
                  total affected area involves at least 35 cm2 of erythema, or total affected area
                  of erythema is at least BSA (m2) x 43.0 (cm2/m2), OR ii. alternatively, involves
                  the central face and is associated with an affected area of at least 15 cm2

               3. Cellulitis, defined as a diffuse skin infection characterized by spreading areas
                  of erythema, edema and/or induration and i. is associated with erythema that
                  involves at least 35 cm2 of surface area, or surface area of erythema is at least
                  BSA (m2) x 43.0 (cm2/m2), OR ii. alternatively, cellulitis of the central face
                  that is associated with an affected area of at least 15 cm2

          -  In addition to the requirement for erythema, all patients are required to have at
             least two (2) of the following signs of ABSSSI:

               1. Purulent drainage/discharge

               2. Fluctuance

               3. Heat/localized warmth

               4. Tenderness to palpation

               5. Swelling/induration

        Exclusion Criteria:

          -  Clinically significant renal impairment, defined as calculated creatinine clearance of
             less than 30 mL/min.

          -  Clinically significant hepatic impairment, defined as serum bilirubin or alkaline
             phosphatase greater than 2 times the upper limits of normal (ULN) for age, and/or
             serum aspartate aminotransferase (AST) or alanine transaminase (ALT) greater than 3
             times the upper limits of normal (ULN) for age.

          -  Treatment with an investigational drug within 30 days preceding the first dose of
             study medication.

          -  Patients with sustained shock defined as systolic blood pressure &lt; 90 mm Hg in
             children ≥ 10 years old, &lt; 70 mm Hg + [2 x age in years] in children 1 to &lt;10 years,
             or &lt; 70 mmHg in infants 3 to &lt;12 months old for more than 2 hours despite adequate
             fluid resuscitation, with evidence of hypoperfusion or need for sympathomimetic agents
             to maintain blood pressure.

          -  Receipt of a systemically or topically administered antibiotic with a Gram-positive
             spectrum that achieves therapeutic concentrations in the serum or at the site of the
             skin infection within 14 days prior to randomization. An exception is allowed for
             patients receiving a single dose of a short-acting (half-life ≤ 12 hours)
             antibacterial drug prior to randomization.

          -  Infection due to an organism known prior to study entry to be resistant to dalbavancin
             (dalbavancin minimum inhibitory concentration (MIC) greater than 0.25 ug/mL) or
             vancomycin (vancomycin minimum inhibitory concentration (MIC) greater than 2 ug/mL).

          -  Patients with necrotizing fasciitis, or deep-seated infections that would require &gt; 2
             weeks of antibiotics (e.g., endocarditis, osteomyelitis or septic arthritis).

          -  Infections caused exclusively by Gram-negative bacteria (without Gram-positive
             bacteria present) and infections caused by fungi, whether alone or in combination with
             a bacterial pathogen.

          -  Venous catheter entry site infection.

          -  Infections involving diabetic foot ulceration, perirectal abscess or a decubitus
             ulcer.

          -  Patient with an infected device, even if the device is removed. Examples include
             infection of: prosthetic cardiac valve, vascular graft, a pacemaker battery pack,
             joint prosthesis, implantable pacemaker or defibrillator, intra-aortic balloon pump,
             left ventricular assist device, or a neurosurgical device such as a ventricular
             peritoneal shunt, intra-cranial pressure monitor, or epidural catheter.

          -  Gram-negative bacteremia, even in the presence of Gram-positive infection or
             Gram-positive bacteremia. Note: If a Gram-negative bacteremia develops during the
             study, or is subsequently found to have been present at Baseline, the patient should
             be removed from study treatment and receive appropriate antibiotic(s) to treat the
             Gram-negative bacteremia.

          -  Patients whose skin infection is the result of having sustained full or partial
             thickness burns.

          -  Patients with uncomplicated skin infections such as superficial/simple
             cellulitis/erysipelas, impetiginous lesion, furuncle, or simple abscess that only
             requires surgical drainage for cure.

          -  Concomitant condition requiring any antibiotic therapy that would interfere with the
             assessment of study drug for the condition under study.

          -  Sickle cell anemia

          -  Cystic fibrosis

          -  Anticipated need of antibiotic therapy for longer than 14 days.

          -  Patients who are placed in a hyperbaric chamber as adjunctive therapy for the ABSSSI.

          -  More than 2 surgical interventions (defined as procedures conducted under sterile
             technique and typically unable to be performed at the bedside) for the skin infection,
             or patients who are expected to require more than 2 such interventions.

          -  Medical conditions in which chronic inflammation may preclude assessment of clinical
             response to therapy even after successful treatment (e.g., chronic stasis dermatitis
             of the lower extremity).

          -  Immunosuppression/immune deficiency, including hematologic malignancy, recent bone
             marrow transplant (in post-transplant hospital stay), absolute neutrophil count &lt; 500
             cells/mm3, receiving immunosuppressant drugs after organ transplantation, receiving
             oral steroids ≥ 20 mg prednisolone per day (or equivalent) for &gt; 14 days prior to
             enrollment, and known or suspected human immunodeficiency virus (HIV) infected
             patients with a CD4 cell count &lt; 200 cells/mm3 or with a past or current acquired
             immunodeficiency syndrome (AIDS)-defining condition and unknown CD4 count.

          -  Known or suspected hypersensitivity to glycopeptide antibiotics, beta-lactam agents,
             aztreonam, or cephalosporins.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Months</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Urania Rappo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Allergan plc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Clinical Trial Registries Team</last_name>
    <phone>877-277-8566</phone>
    <email>IR-CTRegistration@allergan.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of South Alabama</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maricopa Integrated Health System</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85008</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Southbay Pharma Research</name>
      <address>
        <city>Buena Park</city>
        <state>California</state>
        <zip>90620</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of California Los Angeles campus</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Revival Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Global Research Holdings, LLC</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Healthcare of Atlanta</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Mercy Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Our Lady of Lake Regional Medical Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Maryland Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Childen's Hospital of Michigan</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Missouri Dermatology and Skin Surgery</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65212</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>New York University School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Clinical Trial Center</name>
      <address>
        <city>Jenkintown</city>
        <state>Pennsylvania</state>
        <zip>19046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center - 1 Sevlievo EOOD</name>
      <address>
        <city>Sevlievo</city>
        <state>Gabrovo</state>
        <zip>5400</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT (Multiprofile Hospital for Active Treatment)</name>
      <address>
        <city>Kozloduy</city>
        <zip>3320</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MHAT (Multiprofile Hospital for Active Treatment) Ruse, AD Pediatric Department</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Ruse AD, Ruse (MBAL Ruse)</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment (UMHAT)</name>
      <address>
        <city>Stara Zagora</city>
        <zip>6000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Vicente de Paul en Medellin</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>50010</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General de Medellin Luz Castro de Gutierrez</name>
      <address>
        <city>Medellin</city>
        <state>Antioquia</state>
        <zip>500515</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fundacion Cardio Infantil</name>
      <address>
        <city>Bogota</city>
        <zip>110131</zip>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti Batumi Maternal and Child Healthcare Center</name>
      <address>
        <city>Batumi</city>
        <zip>6010</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LEPL Tbilisi State Medical University Givi Zhvania Academic Clinic of Pediatry</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD M. Iashvili Children's Central Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LTD Unimedi Kakheti Children New Hospital</name>
      <address>
        <city>Tbilisi</city>
        <zip>159</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liepaja Regional Hospital</name>
      <address>
        <city>Liepaja</city>
        <state>Kurzeme</state>
        <zip>LV-3414</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Daugavpils Regional Hospital</name>
      <address>
        <city>Daugavpils</city>
        <zip>LV-5417</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <zip>LV-1004</zip>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital of Lithuanian University of Health Sciences Kauno Klinikos</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Klaipeda Children's Hospital</name>
      <address>
        <city>Klaipeda</city>
        <zip>LT- 92144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Children's Hospital, Affiliate of Vilnius University Hospital Santariskiu Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Déu</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>Donostia-San Sebastian</city>
        <state>Gipuzkoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15076</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Colombia</country>
    <country>Georgia</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 8, 2016</study_first_submitted>
  <study_first_submitted_qc>June 23, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 28, 2016</study_first_posted>
  <last_update_submitted>June 6, 2017</last_update_submitted>
  <last_update_submitted_qc>June 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
    <mesh_term>Staphylococcal Infections</mesh_term>
    <mesh_term>Skin Diseases, Infectious</mesh_term>
    <mesh_term>Staphylococcal Skin Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dalbavancin</mesh_term>
    <mesh_term>Teicoplanin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

